– WATCH
Learn more about Bexion Pharmaceuticals through our highlights video
– WATCH
Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson
In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer’s, Parkinson’s, and even infectious diseases such as viruses and bacteria. Hearing from experts in the field, audiences will discover how Bexion Pharmaceuticals, Inc. (Bexion) – a clinical stage biotech company– is leveraging the lysosome’s role to treat even very advanced cancers and improve patient’s quality of life.
– WATCH
Dr. Richard Curry, III Medical Director at CTI and Medical Affairs Advisory at Bexion Pharmaceuticals, Inc. recently presented at the 3rd Annual Glioblastoma Drug Development Summit.
Bexion in Innovation Express
Innovation Express is a multi-media healthcare news hub designed to share all Innovation Healthcare Institute (IHCI) events and programs and announce the most innovative items in healthcare. Bexion Pharmaceuticals, Inc. was recently featured in Innovations Express. Please click on the link below to read the article and learn more about our organization.
– Our Platform
An innovative, targeted approach to treating cancer
For the last 20 years since the mapping of the human genome, many cancer therapeutics have targeted cellular mutations and not the cancer cells’ environment.
By utilizing a small lysosomal protein known as Saposin C our approach specifically targets unique features of cancer cells and their environment, including externalized phosphatidylserine and tumor cell lysosomes.
– Our Pipeline
A Pipeline-in-a-Product asset with potential for multiple indications
BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.
– clinical trials
Update
Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Resources
Resources
News
Bexion Pharmaceuticals, Inc. Announces First Patient Dosed with BXQ-350 in the RETRO Clinical Study
Study Aims to Assess Potential for BXQ-350 to Reduce the Intensity and/or Duration of Chemotherapy-Induced Peripheral Neuropathy (CIPN), a Prevalent Limitation of Existing Chemotherapies FOR IMMEDIATE RELEASE Covington, KY, October 18, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient ... Read More
Bexion Pharmaceuticals, Inc. to Present at the 2022 European Association of Neuro-Oncology (EANO 2022)
FOR IMMEDIATE RELEASE [Covington, KY--- 14 September 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that an abstract submitted for an in-person session at the EANO annual meeting to be held in Vienna, Austria ... Read More